Navidea Biopharmaceuticals Inc  

(Public, NYSEMKT:NAVB)   Watch this stock  
Find more results for OTC:NEOP
1.43
+0.09 (6.72%)
Jun 2 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 1.30 - 1.45
52 week 0.97 - 2.02
Open 1.35
Vol / Avg. 648,261.00/432,551.00
Mkt cap 201.98M
P/E     -
Div/yield     -
EPS -0.21
Shares 150.73M
Beta 0.91
Inst. own 33%
Aug 4, 2015
Q2 2015 Navidea Biopharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Jul 17, 2015
Navidea Biopharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 9:00AM EDT - Add to calendar
Jun 1, 2015
Navidea Biopharmaceuticals Inc at Jefferies Global Healthcare Conference - Webcast
May 12, 2015
Q1 2015 Navidea Biopharmaceuticals Inc Earnings Call - Webcast
May 12, 2015
Q1 2015 Navidea Biopharmaceuticals Inc Earnings Release
Mar 5, 2015
Q4 2014 Navidea Biopharmaceuticals Inc Earnings Release
Mar 5, 2015
Q4 2014 Navidea Biopharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -345.81% -569.36%
Operating margin -370.70% -481.97%
EBITD margin - -432.40%
Return on average assets -256.11% -136.79%
Return on average equity - -
Employees 46 -
CDP Score - -

Address

5600 Blazer Pkwy Ste 200
DUBLIN, OH 43017-7550
United States - Map
+1-614-7937500 (Phone)
+1-614-7937522 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. The Company’s radiopharmaceutical development programs included Lymphoseek (technetium Tc 99m tilmanocept) Injection is a receptor-targeted, small-molecule radiopharmaceutical used in lymphatic mapping procedures that are performed to help evaluate patients with breast cancer and melanoma; Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on macrophages; NAV4694 is a Fluorine-18 (F-18) radiolabeled PET imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer’s disease (AD) and mild cognitive impairment (MCI); among others.

Officers and directors

Gordon A. Troup Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Ricardo J. Gonzalez Chief Executive Officer, Director
Age: 44
Bio & Compensation  - Reuters
Brent L. Larson CPA Chief Financial Officer, Executive Vice President, Treasurer, Secretary
Age: 51
Bio & Compensation  - Reuters
Frederick O. Cope Ph.D. Senior Vice President - Pharmaceutical Research and Clinical Development, Chief Scientific Officer
Age: 68
Bio & Compensation  - Reuters
William J. Regan Senior Vice President - Global Regulatory Affairs and Quality Chief Compliance Officer
Age: 63
Bio & Compensation  - Reuters
Thomas J. Klima Senior Vice President and Chief Commercial Officer
Age: 43
Bio & Compensation  - Reuters
Cornelia B. Reininger M.D., Ph.D. Senior Vice President, Chief Medical Officer
Age: 62
Bio & Compensation  - Reuters
Thomas H. Tulip Ph.D. Chief Business Officer
Age: 62
Bio & Compensation  - Reuters
Michael M. Goldberg M.D. Director
Age: 56
Bio & Compensation  - Reuters
Eric K. Rowinsky M.D. Director
Age: 58
Bio & Compensation  - Reuters